Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 4/20 | 0.59 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | HSP90AB1 | P08238 | 14/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 13/20 | 0.49 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.44 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129642 | 0.81 | CDK1 (0.68) | CDK1CCNB1CCNE1CDK2HSP90AB1 | |
| SCHEMBL183035 | 0.81 | CDK1 (0.68) | CDK1CCNB1CCNE1CDK2YTHDC1 | |
| SCHEMBL29426225 | 0.81 | CDK1 (0.68) | CDK1CCNB1CCNE1CDK2YTHDC1 | |
| SCHEMBL7289687 | 0.79 | CDK1 (0.51) | CDK1CCNB1CCNE1CDK2YTHDC1 | |
| SCHEMBL10148680 | 0.79 | CDK1 (0.57) | CDK1CCNB1CCNE1CDK2HSP90AB1 | |
| SCHEMBL17040218 | 0.79 | HSP90AB1 (0.47) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL8080153 | 0.79 | HSP90AB1 (0.47) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL24474430 | 0.78 | HSP90AB1 (0.46) | HSP90AB1HSP90AA1HSP90B1TRAP1 | |
| SCHEMBL380974 | 0.78 | CDK1 (0.50) | CDK1CCNB1CCNE1CDK2HSP90AB1 | |
| SCHEMBL4378141 | 0.78 | CDK1 (0.50) | CDK1CCNB1CCNE1CDK2YTHDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4217346-B1 | NEW COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-02 | — | — | EP | disclosed |
| CN-117777136-B | 1, 3-Disubstituted tetrahydropyrrole derivative and preparation method and application thereof | 沈阳药科大学 | 2025-04-29 | — | — | CN | disclosed |
| CN-117777136-A | 1, 3-disubstituted tetrahydropyrrole derivative and preparation method and application thereof | 沈阳药科大学 | 2024-03-29 | — | — | CN | disclosed |
| CN-117720538-A | 1, 3-disubstituted piperidine derivative and preparation method and application thereof | 沈阳药科大学 | 2024-03-19 | — | — | CN | disclosed |
| US-20230391756-A1 | NEW COMPOUND | JANSSEN PHARMACEUTICA NV (BE) | 2023-12-07 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| CN-116323585-A | New compounds | 詹森药业有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230159534-A1 | ADENOSINE RECEPTOR ANTAGONIST COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-05-25 | — | — | US | disclosed |
| CN-1353713-A | Purine inhibitors of cyclin dependent kinase 2 and IK B-alpha | CV THERAPEUTICS INC (US) | 2002-06-12 | — | — | CN | disclosed |
| US-20020035252-A1 | Purine inhibitors of cyclin dependent kinase 2 & IkBa | LUM ROBERT T (US) | 2002-03-21 | — | — | US | disclosed |
| US-20020032327-A1 | Purine inhibitors of cyclin dependent kinase 2 & IkappaBalpha | CV THERAPEUTICS, INC. | 2002-03-14 | — | — | US | disclosed |
| EP-1150982-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND I$g(k)-A$g(a) | CV THERAPEUTICS, INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000044750-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND Iλ-A$g(a) | CV THERAPEUTICS, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
| EP-1021186-A4 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha | CV THERAPEUTICS INC (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-1021186-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha | CV THERAPEUTICS, INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1998005335-A9 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) | — | 1998-05-28 | — | — | WO | disclosed |
| WO-1998005335-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) | CV THERAPEUTICS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| EP-0502690-A2 | Cyclopropane derivative | Ajinomoto Co., Inc. (JP) | 1992-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | CDK1 311/4885CCNB1 903/4885CCNE1 901/4885 |
| US-20230391756-A1 | NEW COMPOUND | NLRP3, NLRP1, IL1R1 | CDK1 1410/4885CCNB1 2251/4885CCNE1 1730/4885 |
| US-20230159534-A1 | ADENOSINE RECEPTOR ANTAGONIST COMPOUNDS | ADORA2A, ADORA1, ADORA3 | CDK1 725/4885CCNB1 2165/4885CCNE1 2359/4885 |
| US-20020032327-A1 | Purine inhibitors of cyclin dependent kinase 2 & IkappaBalpha | CDKN1A, CCNK, CDK1 | CDK1 3/4885CCNB1 43/4885CCNE1 82/4885 |
| US-20020035252-A1 | Purine inhibitors of cyclin dependent kinase 2 & IkBa | AURKB, CDKN1A, IKBKB | CDK1 4/4885CCNB1 18/4885CCNE1 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.